Evidence map›Paper›PMID 37058687›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.

Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, Bradley J Monk, Helen Mackay, Alessandro D Santin, David S Miller, Richard G Moore, Sally Baron-Hay, Isabelle Ray-Coquard and 11 more

Open access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 7 pooled it
38.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 7 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Observational

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 20 institutions in 11 countries.

Vicky MakkerMedical Oncology, Memorial Sloan-Kettering Cancer Center, New York City, NY.ORCID 0000-0001-9793-7614
Nicoletta ColomboGynecologic Oncology Department, University of Milan-Bicocca, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0003-2225-715X
Antonio Casado HerráezMedical Oncology Department, Hospital Clinico Universitario San Carlos, Madrid, Spain.
Bradley J MonkHonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ.ORCID 0000-0001-6985-0159
Helen MackayMedical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Alessandro D SantinDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT.
David S MillerDivision of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-8215-5887
Richard G MooreDivision of Gynecologic Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.ORCID 0000-0001-5598-5263
Sally Baron-HayMedical Oncology Department, Royal North Shore Hospital, St Leonards, NSW, Australia.ORCID 0000-0002-9748-1458
Isabelle Ray-CoquardMedical Oncology Department, Centre Léon Bérard, University Claude Bernard, GINECO Group, Lyon, France.ORCID 0000-0003-2472-8306
Kimio UshijimaDepartment of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.ORCID 0000-0002-6087-8873
Kan YonemoriDepartment of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Japan.ORCID 0000-0002-7624-7611
Yong Man KimDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea.
Eva M Guerra AliaDepartment of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Ulus A SanliIndividualized Medicine Application and Research Center and Department of Medical Oncology, Ege University, Izmir, Turkey.ORCID 0000-0002-0062-6105
Steven BirdMerck & Co, Inc, Rahway, NJ.
Robert OrlowskiMerck & Co, Inc, Rahway, NJ.
Jodi McKenzieEisai Inc, Nutley, NJ.ORCID 0000-0002-6345-1218
Chinyere OkparaEisai Ltd, Hatfield, United Kingdom.ORCID 0000-0002-5621-9138
Gianmaria BarresiMSD Switzerland, Zurich, Switzerland.
Domenica LorussoDivision of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy.ORCID 0000-0003-0981-0598
Merck & Co., Inc., Rahway, NJ, USA (United States) · USAgostino Gemelli University Polyclinic · ITAsan Medical Center · KRCreighton University · USEge University · TREisai (United Kingdom) · GBEisai (United States) · USHospital Clínico San Carlos · ESHospital Universitario Ramón y Cajal · ESKurume University · JPMemorial Sloan Kettering Cancer Center · USMSD (Switzerland) · CHNational Cancer Center Hospital East · JPRoyal North Shore Hospital · AUSunnybrook Health Science Centre · CAThe University of Texas Southwestern Medical Center · USUniversité Claude Bernard Lyon 1 · FRUniversity of Milan · ITUniversity of Rochester Medical Center · USYale University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedEndometrial NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolines

Identifiers

PMID37058687
PMCPMC10414727
OpenAlexW4365503784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.